---
figid: PMC9454726__cancers-14-04332-g001
pmcid: PMC9454726
image_filename: cancers-14-04332-g001.jpg
figure_link: /pmc/articles/PMC9454726/figure/cancers-14-04332-f001/
number: Figure 1
figure_title: ''
caption: 'A synthetic lethality therapeutic approach: poly(ADP) ribose polymerase
  inhibitors (PARPi) for the treatment of cancers with a deficient homologous recombination
  repair (HRR) pathway. Neither PARPi nor HRR deficiency (HRD) alone is lethal, but
  the inadequate repair of double-strand breaks found in HRR-deficient cells renders
  them sensitive to PARP inhibition.'
article_title: 'PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.'
citation: Maria Clara Saad Menezes, et al. Cancers (Basel). 2022 Sep;14(17):4332.
year: '2022'

doi: 10.3390/cancers14174332
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI

keywords:
- breast cancer
- PARPi
- BRCA1
- BRCA2
- PALB2
- homologous recombination repair
- HRD

---
